Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for tunneled cuffed dialysis catheter patency
IRCT20211026052874N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of rivaroxaban in end-stage kidney disease (ESKD) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Incidence of intraluminal thrombosis at 6 months, Catheter patency rate at 6 months and 1 more. Started Aug 2024; status: completed.
02
Drugs
rivaroxaban
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20211026052874N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211026052874N1.